Annual EBITDA
-$158.40 M
-$35.57 M-28.95%
December 31, 2023
Summary
- As of February 7, 2025, ALXO annual EBITDA is -$158.40 million, with the most recent change of -$35.57 million (-28.95%) on December 31, 2023.
- During the last 3 years, ALXO annual EBITDA has fallen by -$114.94 million (-264.47%).
- ALXO annual EBITDA is now -1095.05% below its all-time high of -$13.26 million, reached on December 31, 2018.
Performance
ALXO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$30.04 M
+$8.71 M+22.49%
September 30, 2024
Summary
- As of February 7, 2025, ALXO quarterly EBITDA is -$30.04 million, with the most recent change of +$8.71 million (+22.49%) on September 30, 2024.
- Over the past year, ALXO quarterly EBITDA has increased by +$20.35 million (+40.39%).
- ALXO quarterly EBITDA is now -926.91% below its all-time high of -$2.92 million, reached on September 30, 2019.
Performance
ALXO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$148.58 M
+$20.35 M+12.05%
September 30, 2024
Summary
- As of February 7, 2025, ALXO TTM EBITDA is -$148.58 million, with the most recent change of +$20.35 million (+12.05%) on September 30, 2024.
- Over the past year, ALXO TTM EBITDA has dropped by -$4.71 million (-3.28%).
- ALXO TTM EBITDA is now -3495.76% below its all-time high of -$4.13 million, reached on March 31, 2019.
Performance
ALXO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ALXO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -28.9% | +40.4% | -3.3% |
| 3 y3 years | -264.5% | -22.7% | -58.6% |
| 5 y5 years | -1095.0% | -111.5% | -182.8% |
ALXO EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -89.9% | at low | -22.7% | +40.4% | -78.1% | +12.1% |
| 5 y | 5-year | -744.4% | at low | -486.4% | +40.4% | -692.0% | +12.1% |
| alltime | all time | -1095.0% | at low | -926.9% | +40.4% | -3495.8% | +12.1% |
ALX Oncology Holdings EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$30.04 M(-22.5%) | -$148.58 M(-12.0%) |
| Jun 2024 | - | -$38.75 M(+10.9%) | -$168.93 M(+3.2%) |
| Mar 2024 | - | -$34.94 M(-22.1%) | -$163.76 M(+3.4%) |
| Dec 2023 | -$158.40 M(+29.0%) | -$44.85 M(-11.0%) | -$158.40 M(+10.1%) |
| Sep 2023 | - | -$50.39 M(+50.1%) | -$143.86 M(+11.8%) |
| Jun 2023 | - | -$33.58 M(+13.5%) | -$128.70 M(+0.6%) |
| Mar 2023 | - | -$29.58 M(-2.4%) | -$127.95 M(+4.2%) |
| Dec 2022 | -$122.84 M(+47.3%) | -$30.31 M(-14.0%) | -$122.84 M(+1.6%) |
| Sep 2022 | - | -$35.22 M(+7.3%) | -$120.88 M(+9.7%) |
| Jun 2022 | - | -$32.83 M(+34.2%) | -$110.23 M(+17.7%) |
| Mar 2022 | - | -$24.47 M(-13.7%) | -$93.69 M(+12.3%) |
| Dec 2021 | -$83.42 M | -$28.35 M(+15.4%) | -$83.42 M(+15.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$24.57 M(+50.8%) | -$72.48 M(+25.3%) |
| Jun 2021 | - | -$16.29 M(+14.7%) | -$57.82 M(+10.0%) |
| Mar 2021 | - | -$14.20 M(-18.4%) | -$52.54 M(+20.9%) |
| Dec 2020 | -$43.46 M(+131.7%) | -$17.41 M(+75.6%) | -$43.46 M(+29.1%) |
| Sep 2020 | - | -$9.91 M(-10.0%) | -$33.67 M(+26.2%) |
| Jun 2020 | - | -$11.01 M(+115.0%) | -$26.68 M(+35.1%) |
| Mar 2020 | - | -$5.12 M(-32.8%) | -$19.75 M(+5.3%) |
| Dec 2019 | -$18.76 M(+41.5%) | -$7.62 M(+160.6%) | -$18.76 M(+68.4%) |
| Sep 2019 | - | -$2.92 M(-28.3%) | -$11.14 M(+35.6%) |
| Jun 2019 | - | -$4.08 M(-1.3%) | -$8.21 M(+98.7%) |
| Mar 2019 | - | -$4.13 M | -$4.13 M |
| Dec 2018 | -$13.26 M | - | - |
FAQ
- What is ALX Oncology Holdings annual EBITDA?
- What is the all time high annual EBITDA for ALX Oncology Holdings?
- What is ALX Oncology Holdings annual EBITDA year-on-year change?
- What is ALX Oncology Holdings quarterly EBITDA?
- What is the all time high quarterly EBITDA for ALX Oncology Holdings?
- What is ALX Oncology Holdings quarterly EBITDA year-on-year change?
- What is ALX Oncology Holdings TTM EBITDA?
- What is the all time high TTM EBITDA for ALX Oncology Holdings?
- What is ALX Oncology Holdings TTM EBITDA year-on-year change?
What is ALX Oncology Holdings annual EBITDA?
The current annual EBITDA of ALXO is -$158.40 M
What is the all time high annual EBITDA for ALX Oncology Holdings?
ALX Oncology Holdings all-time high annual EBITDA is -$13.26 M
What is ALX Oncology Holdings annual EBITDA year-on-year change?
Over the past year, ALXO annual EBITDA has changed by -$35.57 M (-28.95%)
What is ALX Oncology Holdings quarterly EBITDA?
The current quarterly EBITDA of ALXO is -$30.04 M
What is the all time high quarterly EBITDA for ALX Oncology Holdings?
ALX Oncology Holdings all-time high quarterly EBITDA is -$2.92 M
What is ALX Oncology Holdings quarterly EBITDA year-on-year change?
Over the past year, ALXO quarterly EBITDA has changed by +$20.35 M (+40.39%)
What is ALX Oncology Holdings TTM EBITDA?
The current TTM EBITDA of ALXO is -$148.58 M
What is the all time high TTM EBITDA for ALX Oncology Holdings?
ALX Oncology Holdings all-time high TTM EBITDA is -$4.13 M
What is ALX Oncology Holdings TTM EBITDA year-on-year change?
Over the past year, ALXO TTM EBITDA has changed by -$4.71 M (-3.28%)